This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?
by Zacks Equity Research
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities.
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RFG
Ecolab Set to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Robust segmental performances are likely to have driven ECL's performance in the fourth quarter.
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal Health to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Despite recent supply-chain challenges, new facilities and growth in branded and specialty pharmaceutical sales are likely to have driven CAH's performance in the fiscal second quarter.
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical Surges 62.1% in a Year: What's Driving the Stock?
by Zacks Equity Research
GMED's strong synergies from the NuVasive merger and robust performance in the musculoskeletal solutions space bode well for investors.
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Globus Medical (GMED) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues
by Zacks Equity Research
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow
by Debasmita Chatterjee
Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport.
Reasons to Add GMED Stock to Your Portfolio Right Now
by Zacks Equity Research
Globus Medical's synergistic merger with NuVasive and a strong liquidity position bring optimism to investors.
Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks?
by Zubia Masood
The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty.
Reasons to Ratain CVS Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about CVS Health's 2025 roadmap. Yet, poor macroeconomic conditions are concerning.
Reasons to Retain ABT Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the EPD and Nutrition businesses. Yet, unfavorable forex impacts are concerning.
Reasons to Retain STE Stock in Your Portfolio Now
by Zacks Equity Research
STERIS' strong prospects in the healthcare business bode well for investors.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PDCO Stock Gains on the News of Acquisition Deal With Patient Square
by Zacks Equity Research
Patterson enters into a definitive agreement to be acquired by Patient Square Capital at a valuation of approximately $4.1 billion.
Baxter Stock May Gain Following Five New Injectable Product Launches
by Zacks Equity Research
BAX launches five new injectible products in the United States, thus further strengthening its U.S Pharmaceuticals business segment.
Reasons to Retain Alcon Stock in Your Portfolio for Now
by Zacks Equity Research
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
Reasons to Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
MBOT Stock Gains Following FDA Submission of the LIBERTY System
by Zacks Equity Research
Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.